OSTE Osteotech, Inc. featured news, full reports, and detailed charts
Osteotech, Inc. (OSTE) Wrap Up:
Information contained throughout this Annual Report contains “forward-looking statements” which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “may”, “will”, “should”, or “anticipates” or the negative thereof or variations thereon or comparable terminology, or by discussions of strategy. No assurance can be given that the future results covered by the forward-looking statements will be achieved. Some of the matters set forth in the “Risk Factors” section of this Annual Report and elsewhere in this Annual Report constitute cautionary statements identifying factors with respect to such forward-looking statements, including certain risks and uncertainties that could cause results to vary materially from the future results indicated in such forward-looking statements. Other factors could also cause actual results to vary materially from the future results indicated in such forward-looking statements. ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f03%2f12%2f0000950123-08-002860.html#FIS_BUSINESS"Osteotech, Inc. (OSTE:NASDAQ)
Snapshot of Osteotech, Inc. (OSTE)
|
OPEN
$3.27
|
PREVIOUS CLOSE
$3.28
|
|
|
DAY HIGH
$3.27
|
DAY LOW
$3.01
|
|
|
52 WEEK HIGH
07/30/09 - $5.04
|
52 WEEK LOW
12/8/08 - $1.31
|
|
|
MARKET CAP
54.8M
|
AVERAGE VOLUME 3 mo
115.5K
|
|
|
DILUTED EPS TTM
$-0.30
|
SHARES OUTSTANDING
18.0M
|
|
|
OSTE Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
related news
Post-Christmas trading was slow on Friday. GMAC will become a bank holding company, while Amazon.com said its holiday season was busy
OSTE Top Compensated Officers
Executives, Board Directors
Key developments for Osteotech, Inc. (OSTE)
Osteotech, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Revenue for the quarter was $23.0 million compared with $24.1 million for the three months ended September 30, 2008. The decline in revenue for the third quarter of 2009 compared with the same period of 2008 was primarily driven by the expected reduction in revenue from the services businesses. Net loss for the third quarter was $1.9 million, or $0.11 per share compared with net income of $58,000 or breakeven for the third quarter of 2008. Operating loss was $1.7 million against income of $0.6 million against last year. Loss before income taxes was $2.0 million against income of $0.1 million last year. Revenue for the nine-month period ended September 30, 2009 was $70.4 million compared with $79.2 million reported for the same period of 2008. The decline in revenue for the nine-month period ended September 30, 2009 was primarily driven by the expected reduction in revenue from the company's services businesses, which declined $5.2 million, the aforementioned decline in international revenue and lower domestic unit sales volume. Net loss for the nine-months was $4.9 million or $0.27 per share compared with net income of $2.6 million or $0.15 per diluted share for the comparable period of 2008. The net loss in 2009 is primarily due to the company's anticipated reductions in revenue and lower gross margins and, in the third quarter, higher-than-anticipated costs related to a variety of enhancements to its new procedure-specific biologic solutions. Operating loss was $4.2 million against income of $2.8 million against last year. Loss before income taxes was $5.2 million against income of $3.0 million last year. The company is updating the financial guidance it previously established for 2009. Revenue is expected to range between $92 million and $94 million, Net loss for 2009 is expected to be between $0.32 and $0.36 per share.
Osteotech, Inc., Q3 2009 Earnings Call, Nov-06 2009
Osteotech, Inc. expected to Report Fiscal Year 2009 Results on March 1, 2010. This event was calculated by Capital IQ (Created on October 30, 2009).
OSTE Competitors
| Company | Last | Change |
| Alphatec Holdings Inc | $4.19 USD | -0.23 |
| Cryolife Inc | $6.11 USD | +0.12 |
| Orthovita Inc | $3.75 USD | +0.01 |
| RTI Biologics Inc | $3.89 USD | +0.10 |
| Synovis Life Technologies Inc | $11.99 USD | +0.03 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | OSTE | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.6x |
|
| Price/Book | 0.7x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 0.3x |
|
|
OSTE |
||
OSTE transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||